改良TOPSIS法对抗过敏性鼻炎药效益风险的综合评价  

Evaluation of Risk and Benefit of Anti-allergic Rhinitis Drugs with the Improved TOPSIS Method

作　　者：雷丹[1] 李青[1] 

机构地区：[1]山西医科大学,太原030001

出　　处：《药物流行病学杂志》2014年第8期461-465,共5页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:采用改良TOPSIS法对抗过敏性鼻炎药进行综合评价,探索抗过敏性鼻炎药适宜的综合评价方法,为合理用药提供依据。方法:资料来源于非索非那定、氯雷他定和西替利嗪治疗过敏性鼻炎的39篇随机对照试验(RCT)文献,以非索非那定、氯雷他定和西替利嗪为评价对象,评价指标包括鼻阻塞、鼻瘙痒、喷嚏、鼻涕、眼部症状、生活质量、医生的评价等12个指标,应用改良TOPSIS法对抗过敏性鼻炎药进行综合评价。结果:非索非那定、氯雷他定和西替利嗪与最优值的相对接近度(Ci)分别为:0.846,0.896,0.585。结论:西替利嗪综合评价值最优,非索非那定次之,氯雷他定最差。Objective：To evaluate the anti-allergic rhinitis drugs with the improved TOPSIS method so as to explore a suitable synthetical evaluation method for anti-allergic rhinitis drugs and to provide evidence for rational drug use.Methods：The data were collected from 39 randomized controlled trials of fexofenadine,loratadine and cetirizine. Fexofenadine,loratadine and cetirizine served as the evaluation unit,and the evaluation included 12 indexes,for example,nasal obstruction,nasal itching,sneezing,running nose,ocular symptoms,quality of life,doctor＇s evaluation and so on. The improved TOPSIS method was used in the synthetical evaluation of anti-allergic rhinitis drugs. Results：The relative proximity to the optimal value of fexofenadine,loratadine and cetirizine were 0. 846,0. 896 and 0. 585. Conclusion：The synthetical evaluation value of cetirizine was the best,followed by fexofenadine and loratadine was the worst.

关 键 词：改良TOPSIS法 抗过敏性鼻炎药 综合评价 

分 类 号：R195.1[医药卫生—卫生统计学]